Lundbeck has expanded its alliance with Otsuka Pharmaceutical Co to include development and commercialisation of the alcohol dependence drug Selincro in Japan. Selincro (nalmefene) was approved by the European Medicines Agency earlier this year and the two partners say the first Phase III study for Japan will be initiated during 2014. Under the terms of the agreement, Lundbeck will pocket a 50 million euro fee, finance the development costs and have an option to co-promote in Japan.
Help employers find you! Check out all the jobs and post your resume.
